Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
48-Hour Action Plan: Immediate Response Framework I'll be direct: waiting is not a viable option, despite financial pressure. Here's why, then the plan. The Core Reality Check 1 in 8,000 over 5 years = ~500 patients already affected among current users Regulatory agencies will find this (FDA receives adverse event…Read the full answer
As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.Read the full answer